Hologic — Merger or Acquisition (February 2017)
10 slides from Hologic's merger presentation, Feb 14, 2017
Slide 1: Forward-looking statements
2 This news release contains forward-looking information that involves risks and uncertainties, including statements about each company’s plans, objectives, expectations and intentions. Such statements include, without limitation: financial or other information based upon or otherwise incorporating
Slide 2: Tender offer additional information
3 The tender offer for the outstanding shares of Cynosure referenced in this document has not yet commenced. This document is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares, nor is it a substitute for the tender offer materials that
Slide 3: Non-GAAP financial measures
4 Hologic has presented the following non-GAAP financial measures in this presentation: constant currency revenues; non-GAAP gross profit; non-GAAP gross margin; non-GAAP operating expenses; non-GAAP income from operations; non-GAAP operating margin; non-GAAP interest expense; non-GAAP pre-tax incom
Slide 4: Transaction Highlights / Strategic Rationale
5 Acquiring Cynosure, a leader in medical aesthetic systems and technologies, for $66.00/share or enterprise value of $1.44 billion Benefits Provides Hologic entry into $2+ billion adjacent market with expected double-digit growth Non-Invasive body contouring is the fastest growing segment Complemen
Slide 5: Cynosure Business Overview
Cynosure is a premium and unique asset in the aesthetics space – with high growth, leadership brands, and broadest portfolio among peers #1 overall market share leader with key positions in fastest growing categories 60% of Cynosure’s business is “non-core” or outside of dermatologists and plastic s
Slide 6: Cynosure product portfolio
7 Body Contouring Additional Technologies Non-Invasive Fat Body Contouring Cellulite Reduction SculpSure Diode Laser Skin Tightening Assisted Liposuction Cellulaze Pellefirm RF Body Precision TX MIS face and neck SmartLipo MIS Laser Women’s Health Mona Lisa Touch Fractional CO2 laser Tattoo & Pigmen
Slide 7: Aesthetics Sector Overview
Preference for non-invasive procedures that avoid anesthesia, surgery and downtime Aging population Rising obesity rates Cadence of improved innovation and demonstrated clinical results driving demand Availability of disposable income for cosmetic procedures Changing dynamic for doctors, leading to
Slide 8: Financial Overview, Financing and Timing
9 Financial Overview Financing Timing Purchase price of $66.00 per share in cash for all outstanding Cynosure shares, representing a total enterprise value of approximately $1.44 billion Financial Impact Consideration Expected to be immediately accretive to non-GAAP EPS $0.03 - $0.05 for the remaind
Slide 9: Acquisition of Cynosure
10 Acquisition of Cynosure February 14, 2017
Slide 10: Acquisition of Cynosure
GIC’ |[TTTTTTTTTT NA Acquisition of Cynosure February 14, 2017 HOLOGIC = 10